5 Methoxy N,N Dimethyltryptamine

DRUG6 trials

Sponsors

GH Research Ireland Limited

Conditions

DepressionHealthy AdultHealthy VolunteersMajor Depressive DisorderTreatment Resistant Depression

Phase 1

Safety of GH001 in Healthy Volunteers

CompletedNCT04640831

GH Research Ireland LimitedHealthy Volunteers

Start: 2019-03-13End: 2019-10-04Updated: 2023-08-15

Clinical Study of GH001 in Depression

CompletedNCT04698603

GH Research Ireland LimitedDepression, Major Depressive Disorder, Treatment Resistant Depression

Start: 2019-11-12End: 2021-11-06Updated: 2023-08-15

Pharmacokinetics of GH001 in Healthy Volunteers

CompletedNCT05163691

GH Research Ireland LimitedHealthy Volunteers

Start: 2021-06-21End: 2021-11-22Updated: 2021-12-20

Safety and Pharmacokinetics of GH002 in Healthy Volunteers

CompletedNCT05753956

GH Research Ireland LimitedHealthy Volunteers

Start: 2022-12-22End: 2023-11-29Updated: 2024-01-25

Pharmacokinetics of GH001 Delivered Via a Proprietary Aerosol Delivery Device in Healthy Subjects

RecruitingNCT06511947

GH Research Ireland LimitedHealthy Volunteers

Start: 2024-08-01End: 2025-02-28Target: 52Updated: 2024-08-07

Pharmacokinetics and Safety of GH001 Delivered Via a GH001 Aerosol Delivery System in Healthy Subjects

Not yet recruitingNCT07540494

GH Research Ireland LimitedHealthy Adult

Start: 2026-04-01End: 2026-05-01Target: 12Updated: 2026-04-20

Related Papers

A phase 1/2 trial to assess safety and efficacy of a vaporized 5-methoxy-N,N-dimethyltryptamine formulation (GH001) in patients with treatment-resistant depression

Frontiers in Psychiatry2023-06-2070 citations